Cargando…

Dupilumab improves health related quality of life: Results from the phase 3 SINUS studies

BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2‐mediated inflammatory disease with high symptom burden and reduced health‐related quality of life (HRQoL). This report aimed to comprehensively understand the effects of dupilumab on domains of HRQoL, their indiv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Stella E., Hopkins, Claire, Mullol, Joaquim, Msihid, Jérôme, Guillemin, Isabelle, Amin, Nikhil, Mannent, Leda P., Li, Yongtao, Siddiqui, Shahid, Chuang, Chien‐Chia, Kamat, Siddhesh, Khan, Asif H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305228/ https://www.ncbi.nlm.nih.gov/pubmed/35034364 http://dx.doi.org/10.1111/all.15222

Ejemplares similares

Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
por: Chuang, Chien‐Chia, et al.
Publicado: (2021)

Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps
por: Gevaert, Philippe, et al.
Publicado: (2023)

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
por: Hopkins, Claire, et al.
Publicado: (2021)

Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
por: Bachert, Claus, et al.
Publicado: (2023)

Development of Sinonasal Outcome Test (SNOT‐22) Domains in Chronic Rhinosinusitis With Nasal Polyps
por: Khan, Asif H., et al.
Publicado: (2021)

Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis
por: Han, Joseph K., et al.
Publicado: (2021)

Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
por: Maspero, Jorge F, et al.
Publicado: (2023)

Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab
por: Khan, Asif H, et al.
Publicado: (2021)

Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials
por: Mullol, Joaquim, et al.
Publicado: (2021)

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
por: Fujieda, Shigeharu, et al.
Publicado: (2021)

The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan
por: Fujieda, Shigeharu, et al.
Publicado: (2020)

Real-World Cost of Nasal Polyps Surgery and Risk of Major Complications in the United States: A Descriptive Retrospective Database Analysis
por: Ge, Wenzhen, et al.
Publicado: (2022)

Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
por: Hopkins, Claire, et al.
Publicado: (2022)

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
por: Bachert, Claus, et al.
Publicado: (2022)

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
por: Hamilton, Jennifer D., et al.
Publicado: (2021)

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
por: Siddiqui, Shahid, et al.
Publicado: (2022)

Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
por: Maspero, Jorge F, et al.
Publicado: (2023)

Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
por: Yosipovitch, Gil, et al.
Publicado: (2023)

Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials
por: Peters, Anju T., et al.
Publicado: (2022)

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
por: Fiocchi, Alessandro G., et al.
Publicado: (2023)

Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)

Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines
por: Wechsler, Michael E., et al.
Publicado: (2021)

Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
por: Jonstam, Karin, et al.
Publicado: (2019)

Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma
por: Bansal, Ashish, et al.
Publicado: (2021)

Conjunctivitis in dupilumab clinical trials
por: Akinlade, B., et al.
Publicado: (2019)

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps
por: Bhattacharyya, Neil, et al.
Publicado: (2019)

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics
por: Busse, William Walter, et al.
Publicado: (2023)

Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry
por: Gall, Rebecca, et al.
Publicado: (2023)

Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials
por: Griffiths, Christopher, et al.
Publicado: (2021)

Did dupilumab unmask smoldering mycosis fungoides?
por: Toker, Michelle, et al.
Publicado: (2023)

The ‘GA²LEN Sinusitis Cohort’: an introduction
por: Vandeplas, Griet, et al.
Publicado: (2015)

Dupilumab-associated blepharoconjunctivitis
por: Paulose, Sefy A., et al.
Publicado: (2019)

Dupilumab for atopic dermatitis
Publicado: (2019)

Ophiasis treated with dupilumab
por: Abercrombie, McKenna, et al.
Publicado: (2021)

Dupilumab-Induced Pancreatitis
por: Jasti, Vivek V., et al.
Publicado: (2023)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects
por: Li, Zhaoyang, et al.
Publicado: (2020)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Poster 1023: Dupilumab suppresses Th2 inflammation in adult asthma and atopic dermatitis
por: Swanson, Brian, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_69n5510jdqv5a4l62rr37u1b07